



9/28/05 | Press Release

DAVA Pharmaceuticals, Inc. Announces Acquisition of VoSpire ER®

Fort Lee, New Jersey, September 28, 2005 -- DAVA Pharmaceuticals, Inc. ("DAVA") announced today that it has entered into an agreement with Odyssey Pharmaceuticals, Inc., a subsidiary of PLIVA d.d., for the purchase of VoSpire ER®, the only albuterol extended release tablet indicated for the treatment of bronchospasms associated with reversible airway disease.

"With the acquisition of VoSpire ER®, we are continuing to enhance our strategic portfolio of generic and specialty pharmaceutical products," quoted John H. Klein, Chairman and Chief Executive Officer of DAVA. "DAVA will continue to build its portfolio and deliver additional niche products to the market throughout 2005 and beyond."

DAVA looks forward to working with its partners across all classes of trade on the revitalizing launch of this key asthma oral solid tablet.

About DAVA Pharmaceuticals

DAVA Pharmaceuticals, a specialty pharmaceutical company, is focused on establishing and marketing a broad portfolio of pharmaceutical products. DAVA Pharmaceuticals is aggressively building its product portfolio through a combination of acquisitions, strategic alliances in-licensing transactions, partnerships and development. For further information, please visit www.davapharma.com.